Switzerland Approves J&J Vaccine Following Pfizer and Moderna
[Asia Economy Reporter Changhwan Lee] On the 22nd (local time), Switzerland approved the COVID-19 vaccine developed by the U.S. pharmaceutical company Johnson & Johnson (J&J).
Switzerland's pharmaceutical regulatory authority, Swissmedic, stated on the same day, "Janssen (J&J's European subsidiary) submitted an application for approval on December 7, 2020," and added, "After carefully reviewing all submitted documents, we have provisionally authorized Janssen's COVID-19 vaccine."
They further explained, "According to the submitted research data, the efficacy rate was 64.2% (ages 18?64) to 82.4% (65 and older) from 14 days after vaccination," and "Positive effects were also demonstrated against variants reported in Brazil and South Africa."
However, they added that the most frequently recorded side effects in clinical trials were headache, fatigue, pain at the injection site, and nausea.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Swissmedic also reported that Pfizer and Moderna vaccines have already been approved in Switzerland, while AstraZeneca's application is still under review.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
